Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines
Background: Triple-negative breast cancer (TNBC) is the most aggressive molecular subtype of breast cancer, and current treatments are only partially effective in disease control. More effective combination approaches are needed to improve the survival of TNBC patients. Eribulin mesylate, a non-taxa...
Main Authors: | Xuemei Xie, Jangsoon Lee, Jon A. Fuson, Huey Liu, Toshiaki Iwase, Kyuson Yun, Cori Margain, Debu Tripathy, Naoto T. Ueno |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/11/3/735 |
Similar Items
-
Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer
by: Wei Wen, et al.
Published: (2019-08-01) -
Targeting PI3K/Akt/mTOR Signaling In Cancer
by: Camillo ePorta, et al.
Published: (2014-04-01) -
Efficacy of Eribulin in Soft Tissue Sarcomas
by: Edward Phillips, et al.
Published: (2022-03-01) -
The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects
by: Eleni A. Karatrasoglou, et al.
Published: (2023-09-01) -
Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation
by: Hyemi Ko, et al.
Published: (2022-04-01)